These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25063383)

  • 1. [Principles of therapeutic approaches for mucopolysaccharidoses].
    Caillaud C
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses.
    Piotrowska E; Jakóbkiewicz-Banecka J; Barańska S; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G
    Eur J Hum Genet; 2006 Jul; 14(7):846-52. PubMed ID: 16670689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and II clinical trials for the mucopolysaccharidoses.
    Poswar F; Baldo G; Giugliani R
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1331-1340. PubMed ID: 29065735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of mucopolysaccharidoses.
    Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
    Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and potential therapeutic strategies for mucopolysaccharidoses.
    Noh H; Lee JI
    J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
    Lau AA; Hemsley KM
    J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology applied to treatment of mucopolysaccharidoses.
    Schuh RS; Baldo G; Teixeira HF
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for Mucopolysaccharidoses.
    Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
    Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the mucopolysaccharidoses.
    Muenzer J
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v4-12. PubMed ID: 22210669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses.
    Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M
    Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and new therapies for mucopolysaccharidoses.
    Penon-Portmann M; Blair DR; Harmatz P
    Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Emerging Therapies for Mucopolysaccharidoses.
    Lagler FB
    Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
    Kakkis E; Marsden D
    Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications.
    Pierzynowska K; Gaffke L; Cyske Z; Węgrzyn G; Buttari B; Profumo E; Saso L
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical review of current MPS guidelines and management.
    Stapleton M; Hoshina H; Sawamoto K; Kubaski F; Mason RW; Mackenzie WG; Theroux M; Kobayashi H; Yamaguchi S; Suzuki Y; Fukao T; Tadao O; Ida H; Tomatsu S
    Mol Genet Metab; 2019 Mar; 126(3):238-245. PubMed ID: 30143438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.